Dr. Alexander B. Olawaiye speaks on how the ROSELLA trial shows relacorilant plus nab-paclitaxel improves survival in ...

Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a ...

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to ...

Dr. Evan Wu presents William, a 76-year-old Black man and former smoker (25 pack-year history, quit 15 years ago) who ...

The rapid evolution of advanced therapies like cell and gene therapies is reshaping the oncology landscape and challenging ...

The FDA granted regenerative medicine advanced therapy (RMAT) designation to Orca-Q, a second-generation investigational ...

A data monitoring committee recommended stopping FLASH2, a randomized double-blind placebo-controlled confirmatory phase 3 ...

Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, explores the safety and tolerability of ...

When comprehensive tissue next-generation sequencing (NGS) fails, liquid biopsy should be the reflex strategy, especially in ...

Dr Dulmage highlights that one of the most frequently overlooked early warning signs of clinically significant dermatologic ...

Switching to camizestrant 75 mg while continuing CDK4/6i significantly prolonged PFS to 16.0 vs 9.2 months (HR 0.44; P<.00001 ...